加载中
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
前收盘价
US$0.2379
−US$0.0001 · -0.04%
盘后
US$0.2385
+US$0.0006 · +0.25%
10月12日 17:27 ET
盘中时间采用ET。市场数据可能有所延迟。
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
日内区间
当前US$0.2379
52周区间
当前US$0.2379
盘中时间采用ET。市场数据可能有所延迟。
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
日内区间
当前US$0.2379
52周区间
当前US$0.2379
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1032.5万 USD | 281.6万 USD | 2104.9万 USD | 1353.5万 USD | 1014.1万 USD |
| 销货成本 | 286.6万 USD | — | — | — | — |
| 毛利 | 745.9万 USD | 281.6万 USD | 2104.9万 USD | 1353.5万 USD | 1014.1万 USD |
| 研究与开发 | 1.14亿 USD | 1.07亿 USD | 8815.3万 USD | 5981.9万 USD | 4495.4万 USD |
| 销售、一般及管理费用 | 3198.8万 USD | 2955.9万 USD | 2549.2万 USD | 2035.2万 USD | 1382.8万 USD |
| 营业费用 | 1.43亿 USD | 1.38亿 USD | 1.15亿 USD | 8017.1万 USD | 5878.2万 USD |
| 利息收入 | 881.6万 USD | 1206.5万 USD | 799.9万 USD | 159.1万 USD | 1.6万 USD |
| 利息支出 | 276.9万 USD | 365.3万 USD | 375.9万 USD | 117.6万 USD | — |
| 折旧和摊销 | 286.6万 USD | 410.8万 USD | 536.1万 USD | 513.7万 USD | 332.8万 USD |
| 营业利润 | −1.36亿 USD | −1.35亿 USD | −9345.8万 USD | −6663.6万 USD | −4864.1万 USD |
| 净利润 | −1.3亿 USD | −1.27亿 USD | −8921.8万 USD | −6622.1万 USD | −4862.5万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$1.00
上涨空间 320.34%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI134.49万0.00%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard Extended Market ETFVXF48.58万0.00%954亿 USD0.05%US$233.52-0.63%
iShares Micro-Cap ETFIWC3.78万0.00%13.17亿 USD0.60%US$181.66-0.73%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM2万0.01%1.16亿 USD0.73%US$15.8484-0.58%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
